Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 15/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | NRAS | P01111 | 4/20 | 0.32 |
| ▸ | CLK2 | P49760 | 2/20 | 0.32 |
| ▸ | CLK3 | P49761 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376763 | 1.00 | FLT3 (0.35) | FLT3IRAK4PIM1PIM2PIM3 | |
| SCHEMBL10239881 | 0.86 | FLT3 (0.33) | FLT3IRAK4PIM1PIM2PIM3 | |
| SCHEMBL376822 | 0.83 | IL1B (0.34) | FLT3IRAK4PIM1PIM2PIM3 | |
| SCHEMBL10239855 | 0.83 | IL1B (0.34) | FLT3IRAK4PIM1PIM2PIM3 | |
| SCHEMBL10238370 | 0.83 | IL1B (0.34) | FLT3IRAK4PIM1PIM2PIM3 | |
| SCHEMBL376409 | 0.83 | IL1B (0.34) | FLT3IRAK4PIM1PIM2PIM3 | |
| SCHEMBL10239835 | 0.82 | FLT3 (0.34) | FLT3IRAK4PIM1PIM2PIM3 | |
| SCHEMBL10239491 | 0.82 | IRAK4 (0.30) | IRAK4 | |
| SCHEMBL10239833 | 0.81 | FLT3 (0.34) | FLT3IRAK4PIM1PIM2PIM3 | |
| SCHEMBL10239478 | 0.81 | FLT3 (0.33) | FLT3IRAK4PIM1PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |